T-Cell Lymphoma Forum 2014


The 6th Annual T-cell Lymphoma Forum took place January 23-25, 2014, in San Francisco, California.


Allo-SCT can be effective in advanced SS, MF

Jen Smith Read Article
Published: 02/07/14

SCT preparation
Credit: Chad McNeeley

A single-center study suggests that transplant can induce remissions and improve survival in certain patients with advanced cutaneous T-cell lymphomas. Allogeneic stem cell transplant (SCT) proved particularly effective in patients with Sézary syndrome (SS). It also conferred benefits to mycosis fungoides (MF) patients with large-cell transformation (LCT), but patients with SS and LCT did not fare as well. These results were presented at the 6th Annual T-cell Lymphoma Forum. [Read Article]

Consortium study falls short of expectations

Jen Smith Read Article
Published: 02/04/14

Ranjana Advani, MD

A group’s effort to identify optimal front-line treatment for peripheral T-cell lymphomas (PTCLs) was not as successful as researchers anticipated. The North American PTCL Consortium set out to find a treatment that could best CHOP, as studies have suggested this regimen is inadequate for patients with PTCL. So the group organized a trial testing a potentially more promising regimen: cyclophosphamide, etoposide, vincristine, and prednisone, alternating with pralatrexate (CEOP-P). [Read Article]

Regimen shows promise for ENKTL

Jen Smith Read Article
Published: 01/31/14

Hui-qiang Huang, MD, PhD

Results of a single-center study suggest that a 3-drug regimen may be a safe and effective treatment option for patients with newly diagnosed or relapsed/refractory extranodal natural killer/T-cell lymphoma (ENKTL). The combination of pegaspargase, gemcitabine, and oxaliplatin (P-Gemox) elicited a high rate of response in this cohort of 60 Chinese patients. P-Gemox also produced higher survival rates than those previously observed with the EPOCH regimen. [Read Article]

TNFRII may play key role in CTCL, speaker says

Jen Smith Read Article
Published: 01/30/14

Dr Alexander Ungewickell

Researchers have found evidence to suggest that tumor necrosis factor receptor II (TNFRII) may be an important driver of cutaneous T-cell lymphomas (CTCLs). The team discovered that a mutation in this receptor—TNFRII T377I—is present in patients with mycosis fungoides (MF) and those with Sézary syndrome (SS). And previous research showed that the region encoding TNFRII on chromosome 1 is sometimes amplified in MF and SS patients.  [Read Article]

Inhibitor appears active in relapsed/refractory TCLs

HT Staff Read Article
Published: 01/29/14

Attendees peruse posters
at TCLF 2014

Preliminary results of a phase 1 trial suggest the PI3K-delta/gamma inhibitor IPI-145 is active in patients with relapsed or refractory T-cell lymphomas. Among 26 evaluable patients, 9 experienced partial responses to treatment with IPI-145, and 1 achieved a complete response, for an overall response rate (ORR) of 38%. The drug also appeared to be well-tolerated, although 30% of patients did experience treatment-related severe adverse events.  [Read Article]

A new prognostic model for PTCL?

Jen Smith Read Article
Published: 01/28/14

Adam Petrich, MD

Unlike its predecessors, a new prognostic model suggests race and histology are important predictors of outcome in patients with peripheral T-cell lymphoma (PTCL). Researchers analyzed nearly 9000 patients diagnosed with PTCL in the US and found evidence to suggest that patient age and race, as well as histology and disease stage can be used to predict overall survival (OS). The group’s findings also suggested the use of radiation is associated with improved OS. [Read Article]


    {icon} {author} Read Article
    Published: {pubDate}